dr. perez discusses a genomic analysis of the ncctg (alliance) n9831 adjuvant trastuzumab trial
Published 10 years ago • 137 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:25
dr. perez discusses a genomic analysis of the ncctg n9831 adjuvant trastuzumab trial
-
1:04
dr. edith perez discusses the adjuvant treatment of breast cancer
-
1:33
dr. perez discusses optimizing adjuvant therapy
-
0:51
dr. perez describes retesting recurrent breast cancer
-
1:15
dr. edith perez discusses adjuvant chemotherapy patient selection
-
0:47
dr. edith perez on adjuvant treatments
-
1:36
dr. perez discusses obesity as a predictive marker
-
7:28
edith a. perez, md: anti-her2 therapies
-
1:08
dr. edith perez on her anticipated results for asco and sabcs
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
2:05
dr. perez discusses the b-34 clodronate study
-
4:15
identifying genes that can predict if breast cancer drug is working - mayo clinic
-
1:32
"what is the nektar trial for women with metastatic breast cancer?"
-
7:30
aphinity trial in her2 breast cancer
-
7:42
breast cancer: genomic testing for adjuvant therapy
-
1:14
prognostic value of beta-2 adrenergic receptor levels in her2 breast cancer
-
33:58
translational genomics: the future is now | edith perez, md
-
5:29
adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in her2-positive breast cancer
-
5:34
neos: prognosis of er breast cancer pts who received neoadjuvant et with/without adjuvant chemo